ES2134051T3 - Procedimiento para la preparacion de sildenafil. - Google Patents

Procedimiento para la preparacion de sildenafil.

Info

Publication number
ES2134051T3
ES2134051T3 ES97303832T ES97303832T ES2134051T3 ES 2134051 T3 ES2134051 T3 ES 2134051T3 ES 97303832 T ES97303832 T ES 97303832T ES 97303832 T ES97303832 T ES 97303832T ES 2134051 T3 ES2134051 T3 ES 2134051T3
Authority
ES
Spain
Prior art keywords
sildenafil
procedure
preparation
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97303832T
Other languages
English (en)
Inventor
Peter James Dunn
Albert Shaw Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134051(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2134051T3 publication Critical patent/ES2134051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

UN PROCEDIMIENTO PARA LA PREPARACION DE UN COMPUESTO DE FORMULA (I) TAMBIEN CONOCIDO COMO SILDENAFIL EL CUAL COMPRENDE LA CICLIZACION DE UN COMPUESTO DE FORMULA (II).
ES97303832T 1996-06-14 1997-06-04 Procedimiento para la preparacion de sildenafil. Expired - Lifetime ES2134051T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (1)

Publication Number Publication Date
ES2134051T3 true ES2134051T3 (es) 1999-09-16

Family

ID=10795332

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97303832T Expired - Lifetime ES2134051T3 (es) 1996-06-14 1997-06-04 Procedimiento para la preparacion de sildenafil.
ES98123740T Expired - Lifetime ES2201397T3 (es) 1996-06-14 1997-06-04 Procedimiento para la preparacion de silidenafilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98123740T Expired - Lifetime ES2201397T3 (es) 1996-06-14 1997-06-04 Procedimiento para la preparacion de silidenafilo.

Country Status (48)

Country Link
US (2) US5955611A (es)
EP (2) EP0916675B1 (es)
JP (2) JP2866841B2 (es)
KR (1) KR100207352B1 (es)
CN (2) CN1106399C (es)
AP (1) AP717A (es)
AR (1) AR003401A1 (es)
AT (2) ATE182150T1 (es)
AU (1) AU697684B2 (es)
BG (1) BG62554B1 (es)
BR (1) BR9703580A (es)
CA (1) CA2207694C (es)
CO (1) CO4780028A1 (es)
CZ (1) CZ290942B6 (es)
DE (2) DE69700321T2 (es)
DK (2) DK0916675T3 (es)
DZ (1) DZ2247A1 (es)
EA (1) EA000102B1 (es)
EG (1) EG24123A (es)
ES (2) ES2134051T3 (es)
GB (1) GB9612514D0 (es)
GR (1) GR3031087T3 (es)
HK (1) HK1033459A1 (es)
HN (1) HN1997000072A (es)
HR (1) HRP970326B1 (es)
HU (1) HU224497B1 (es)
ID (1) ID18745A (es)
IL (3) IL125411A (es)
IN (5) IN187350B (es)
IS (2) IS1922B (es)
MA (1) MA24205A1 (es)
MX (1) MX9704433A (es)
NO (2) NO304551B1 (es)
NZ (1) NZ328084A (es)
OA (1) OA10426A (es)
PE (2) PE1299A1 (es)
PL (1) PL189333B1 (es)
PT (1) PT916675E (es)
RS (2) RS49653B (es)
SA (1) SA97180124B1 (es)
SG (1) SG50024A1 (es)
SI (2) SI0812845T1 (es)
SK (5) SK283893B6 (es)
TN (1) TNSN97102A1 (es)
TR (1) TR199700470A2 (es)
UA (1) UA27085C2 (es)
UY (2) UY24585A1 (es)
ZA (1) ZA975259B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
PL336586A1 (en) * 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 ***机能障碍治疗剂
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
HUP0102543A3 (en) * 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
US6077841A (en) * 1998-09-04 2000-06-20 Janssen Pharmaceutica, N.V. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
AU5204800A (en) * 1999-06-21 2001-01-09 Biochemical Pharmaceutical Factory of Zhuhai Sez, The Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
AU1888800A (en) * 1999-09-13 2001-04-17 Cipla Limited A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1222190A1 (en) 1999-10-11 2002-07-17 Pfizer Limited 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
EP1296983B1 (en) * 2000-06-22 2004-11-17 Pfizer Limited Novel process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
EP1176147A1 (en) * 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
EP1421084B1 (en) * 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和***的新吡唑并嘧啶类化合物
WO2005067936A2 (en) * 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Methods for the production of sildenafil base and citrate salt
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
WO2010067140A1 (es) 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
PL336586A1 (en) * 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
IL125411A (en) 2000-02-29
SA97180124B1 (ar) 2006-02-08
CA2207694C (en) 1999-11-23
DE69723846T2 (de) 2004-03-04
IN187350B (es) 2002-03-30
BG62554B1 (bg) 2000-02-29
IL121000A0 (en) 1997-11-20
AP717A (en) 1999-01-04
IS4503A (is) 1997-12-15
HN1997000072A (es) 1997-12-26
IS6634A (is) 2002-11-25
EG24123A (en) 2008-07-06
NZ328084A (en) 1998-08-26
SG50024A1 (en) 1998-06-15
TR199700470A2 (xx) 1998-01-21
ES2201397T3 (es) 2004-03-16
MA24205A1 (fr) 1997-12-31
EP0812845B1 (en) 1999-07-14
NO972481L (no) 1997-12-15
AU697684B2 (en) 1998-10-15
CA2207694A1 (en) 1997-12-14
DZ2247A1 (fr) 2002-12-18
IS1923B (is) 2004-03-15
IL121000A (en) 2000-02-29
IL125411A0 (en) 1999-03-12
JPH1081688A (ja) 1998-03-31
HUP9701048A2 (hu) 1998-12-28
SK283895B6 (sk) 2004-04-06
PE1299A1 (es) 1999-01-13
IN187320B (es) 2002-03-23
ID18745A (id) 1998-05-07
NO304551B1 (no) 1999-01-11
IN187317B (es) 2002-03-23
HK1033459A1 (en) 2001-08-31
NO972481D0 (no) 1997-05-30
KR980002051A (ko) 1998-03-30
HU224497B1 (hu) 2005-10-28
JP2866841B2 (ja) 1999-03-08
SK283896B6 (sk) 2004-04-06
NO985064D0 (no) 1998-10-30
CZ290942B6 (cs) 2002-11-13
RS49653B (sr) 2007-09-21
UY24612A1 (es) 2000-09-29
DE69700321D1 (de) 1999-08-19
BR9703580A (pt) 1998-11-10
UA27085C2 (uk) 2000-02-28
PT916675E (pt) 2003-11-28
TNSN97102A1 (fr) 2005-03-15
DE69723846D1 (de) 2003-09-04
JPH11171879A (ja) 1999-06-29
RS20060484A (en) 2007-04-10
PL320555A1 (en) 1997-12-22
AP9701009A0 (en) 1997-07-31
JP3058863B2 (ja) 2000-07-04
CZ181197A3 (cs) 1998-03-18
HUP9701048A3 (en) 2000-10-30
ZA975259B (en) 1997-12-15
EA000102B1 (ru) 1998-08-27
IS1922B (is) 2004-03-15
EP0916675A2 (en) 1999-05-19
YU25497A (sh) 1998-12-23
PL189333B1 (pl) 2005-07-29
HRP970326A2 (en) 1998-06-30
IN187318B (es) 2002-03-23
IN187319B (es) 2002-03-23
DK0812845T3 (da) 1999-11-29
RS49924B (sr) 2008-09-29
MX9704433A (es) 1998-11-30
CN1168376A (zh) 1997-12-24
GB9612514D0 (en) 1996-08-14
SI0916675T1 (en) 2003-12-31
SK283893B6 (sk) 2004-04-06
SI0812845T1 (en) 1999-12-31
PE20011303A1 (es) 2001-12-25
CN1106399C (zh) 2003-04-23
GR3031087T3 (en) 1999-12-31
DK0916675T3 (da) 2003-10-27
NO306115B1 (no) 1999-09-20
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
EP0916675B1 (en) 2003-07-30
SA97180124A (ar) 2005-12-03
NO985064L (no) 1997-12-15
OA10426A (en) 2001-12-07
KR100207352B1 (en) 1999-07-15
US6066735A (en) 2000-05-23
BG101569A (en) 1998-01-30
SK74397A3 (en) 1998-06-03
CN1282740A (zh) 2001-02-07
AR003401A1 (es) 1998-08-05
CO4780028A1 (es) 1999-05-26
CN1149206C (zh) 2004-05-12
SK283897B6 (sk) 2004-04-06
US5955611A (en) 1999-09-21
HRP970326B1 (en) 2000-10-31
EP0812845A1 (en) 1997-12-17
AU2487897A (en) 1997-12-18
ATE182150T1 (de) 1999-07-15
ATE246194T1 (de) 2003-08-15
DE69700321T2 (de) 1999-11-04
HU9701048D0 (en) 1997-08-28
EA199700061A1 (ru) 1997-12-30
EP0916675A3 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
ES2134051T3 (es) Procedimiento para la preparacion de sildenafil.
MY126559A (en) Fungicidal 2-methoxybenzophenones
ES557486A0 (es) Procedimiento para la obtencion de comopuestos macropoliciclicos
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
CY1111759T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη συγκεκριμενων τριαζολοπυριμιδινων ως ρ2τ ανταγωνιστων
HRP20030383B1 (en) Lactam compound
DE69803907T2 (de) Fungizide 2-Methoxybenzophenone
DK0857718T3 (da) Endothelinantagonist
WO1999064047A8 (en) Novel antiviral compounds
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
ES2162336T3 (es) Modulo de espectroscopia de correlacion de fluorescencia para un microscopio.
CU23088A3 (es) Compuestos de tetra-hidropiridina.
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
EA200100854A1 (ru) Кальций-литические соединения
HN1998000193A (es) Compuestos de triazina
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
ES2173586T3 (es) Derivados de ciclohexandiol.
DK0915858T3 (da) Mellemprodukter til fremstilling af 2-imidazolin-5-oner
SE9602416D0 (sv) New forms of an organic salt of N'N-diacetylcystine
ECSP972142A (es) Procedimiento para la preparacion de sildenafil
WO2003044877A3 (en) Light emitting device and compounds for use therein
PT1100821E (pt) Compostos anti-inflammatorios derivados de lipocortina-1
GT199900057A (es) Procedimiento para la preparaciòn de ( s , s ) - bencil - 2,8 - diazabiciclo 4.3.0. nonano.
HN1997000136A (es) Tetrahidro 6h pirazino (1,2-b)isoquinolin - 14 dionas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 812845

Country of ref document: ES